We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Committee Rejects Merck's Arcoxia
FDA Advisory Committee Rejects Merck's Arcoxia
April 13, 2007
The FDA’s Arthritis Advisory Committee voted 20-1 against recommending approval of Merck’s Arcoxia, a potential successor to Vioxx as a treatment for arthritis pain.